Fzata, Inc.
Publicly observedHalethorpe, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Halethorpe | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Fzata, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | SLGDVHJS1Y85 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant21 Sept 2026Publicly observed
NIH SBIR/STTR award: Gut-Targeted IL-10 Delivery via Engineered Saccharomyces boulardii to Prevent Immune Checkpoint Inhibitor Colitis
USD 372,153.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant11 Sept 2026Publicly observed
NIH SBIR/STTR award: Development of a Dual-Action Oral Immunotherapy for Clostridioides difficile Prevention
USD 313,095.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.